Kornimate/medical-research-clean huggingface dataset:
tandospirone combined with atypical antipsychotic drugs in schizophrenia

Conditions: Schizophrenia

Summary: efficacy and safety of tandospirone combined with atypical antipsychotic drugs to improve cognitive function in schizophrenia

with atypical antipsychotics for the control group, evaluate cognitive function in schizophrenia patients with antipsychotics combined 5-hydroxytryptamine 1a (5-ht1a) receptor partial agonist tandospirone

Eligibility criteria:
inclusion criteria: * diagnostic and statistical manual of mental disorders-iv edition (dsm-iv) diagnostic criteria for schizophrenia patients. * 18-65 years (including 18 and 65), male or female. * treated with a stable dose of an aapd for at least three months. * informed consent was obtained (if the patient is in the acute phase of schizophrenia, does not have the capacity, their guardians need sign informed consent). * panss negative score ≤60. exclusion criteria: * combined axisⅰmental illness other than schizophrenia; * taking a mood stabilizer, antidepressants, anticholinergic or anxiolytic drugs, and other drugs improve cognitive function; * suicidal tendencies; * have severe or unstable heart, liver, kidney, endocrine, blood and other medical disease patients * clinically significant ecg or laboratory abnormalities were * glaucoma and epilepsy; * unsupervised or unable to take prescribed medication; * history of alcohol and drug abuse; * allergic; * pregnant or lactating woman; * patients participate in other clinical trials during a month;

Keywords: schizophrenia tandospirone cognitive therapy
oral sirolimus for in-stent restenosis

Conditions: Coronary Restenosis

Summary: despite recent advances in interventional cardiology including the success of drug-eluting stents in de-novo coronary lesions, the treatment of in-stent restenosis remains a challenging clinical issue. given the efficacy of the systemic sirolimus administration to prevent neointimal hyperplasia in animal models and to halt and even reverse the progression of allograft vasculopathy, the aim of the present double-blind, placebo-controlled study was to evaluate the efficacy of a 10-day oral sirolimus treatment with two different loading regimens for the prevention of recurrent restenosis in patients with in-stent restenosis.

three-hundred symptomatic patients with in-stent restenotic lesions were randomly assigned to one of three treatment arms: placebo, usual dose or high dose sirolimus. patients received a cumulative loading dose of 0, 8 or 24 mg of sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days. angiographic restenosis at 6-months angiography was the primary end point of the study.

Eligibility criteria:
inclusion criteria: * patients with angina pectoris or exercise-induced ischemia in the presence of angiographically significant in-stent-restenosis in native coronary arteries. exclusion criteria: * patients with acute coronary syndromes or with severe infectious diseases the presence of severe kidney failure (serum creatinine \> 2.2 mg/dl) contraindications to sirolimus

Keywords: in-stent restenosis stents sirolimus
the effect of intramyometrial injection of terlipressin versus carbitocin on hemoglobin and blood loss during open myomectomy operations using haemostatic tourniquets:

Conditions: Myoma

Summary: the study aims to evaluate the efficacy of intramyometrial terlipressin injection versus intramyometrial carbetocin injection on hemoglobin level in women undergoing abdominal myomectomy. moreover, to evaluate their efficacy in decreasing blood loss on operative time and to describe the injection sequelae for the same population. this clinical study will be conducted in compliance with the clinical study protocol and applicable regulatory requirements.

this study is a prospective, comparative, double-blinded randomized placebo-controlled trial and multi-center study that will be conducted at wael elbanna clinic and the nrc site. the study participants' relevant medical records will be collected and reviewed after obtaining informed consent for the participants. data will be pooled and presented in aggregate, without the identification of individual subjects. the study materials that will be used will include blood tests and ultrasound. the study will involve three study arms: * arm 1: intramyometrial terlipressin injection in women undergoing open myomectomy procedure using haemostatic tourniquets. * arm 2: intramyometrial carbetocin injection in women undergoing open myomectomy procedure using haemostatic tourniquets. * arm 3: intramyometrial saline injection in women undergoing open myomectomy procedure using haemostatic tourniquets(placebo). subjects who meet diagnostic requirements as listed in the inclusion and exclusion criteria will be included in the study. women will be randomized to one of the three arms using a computer-generated randomization table with a 1:1:1 group allocation

Eligibility criteria:
inclusion criteria: 1. women aged 16-45 years 2. appropriate medical status for open surgery (largest myoma size from 4 cm up to 20 cm) 3. baseline hemoglobin ≥9 g/dl 4. no contra-indications to the use of glyopressin or carbitocin 5. myoma-related symptoms, such as pelvic pressure or pain, menorrhagia, or infertility 6. not pregnant at the time of presentation exclusion criteria: 1. previous myomectomy 2. history of bleeding disorders 3. concurrent anticoagulation therapy 4. history of uncontrolled ischaemic heart disease 5. any pelvic abnormalities requiring concomitant surgery 6. treatment with a gnrh agonist or ulipristal acetate within three months preceding surgery 7. inability to understand and provide written informed consent.
a 48 week study to evaluate the efficacy and safety of two (2) eys606 treatment regimens in subjects with active chronic non-infectious uveitis (cniu)

Conditions: Non-infectious Uveitis

Summary: the objective of the study is to evaluate the efficacy and safety of two different treatment regimens of eys606.

this is a phase 2, multi-center, randomized open-label interventional study of eys606 in subjects with active chronic non-infectious uveitis. the maximum study duration per patient is 51 weeks (including an up to 3 week screening period + 48 weeks follow-up after treatment). the study will be conducted in 2 parts. part i is a safety cohort phase that will enroll up to 6 subjects, part ii is the randomized comparison phase that will enroll up to an additional 50 subjects.

Eligibility criteria:
key eligibility criteria: 1. subject must be 18 years of age or older. 2. subject must have a diagnosis of chronic non-infectious uveitis of any anatomic subtype (anterior, intermediate, posterior or panuveitis). 3. subject must have a history of chronic or recurrent non-infectious uveitis requiring or having required treatment with corticosteroids (systemic, periocular or intraocular) and/or systemic immunosuppressive medication(s) in the 12 months prior to the screening visit. 4. best corrected visual acuity of * study part i: ≥ 5 and \< 67 etdrs letters in the study eye (equivalent to less than or equal to 20/50 but better than or equal to 20/800 snellen). * study part ii: ≥ 5 and \< 77 etdrs letters in the study eye (equivalent to less than or equal to 20/32 but better than or equal to 20/800 snellen). 5. at the screening and baseline visits subject must have active chronic non-infectious uveitis as evidenced by at least one or more of the following in the study eye: * active retinal vasculitis (retinal vascular leakage) involving the posterior pole confirmed by the reading center. * vitreous haze grade ≥ 2+ (sun classification). * anterior chamber cell grade ≥ 2+ (sun classification); anterior chamber cells must be present for subjects with a diagnosis of chronic anterior non-infectious uveitis. * persistent macular edema (defined as central retinal thickness (crt) \> 300 microns or \> 320 microns using zeiss cirrus and topcon or heidelberg spectralis spectral domain ocular coherence tomography (sd-oct) instruments, respectively) despite treatment with corticosteroids and/or immunosuppressive therapy for at least 4 weeks prior to screening. 6. subject receiving concomitant topical and/or systemic corticosteroids or allowed systemic immunosuppressive medications must have maintained the same treatment regimen (dosage/frequency) for at least 2 weeks prior to the baseline (v1) visit, (if applicable).
a study designed to assess the mass balance recovery, absorption, metabolism, excretion of [14c]azd5462 and the absolute bioavailability of azd5462

Conditions: Heart Failure

Summary: a study to investigate how the body breaks down and gets rid of the test medicine, azd5462. to help investigate this, the test medicine is radiolabelled, which means that the test medicine has a radioactive component (carbon-14), which helps us to track where the test medicine is in the body. the safety and tolerability of the test medicine will also be studied.

this is an open-label, two-period study designed to assess the mass balance recovery, absorption, metabolism, excretion of \[14c\]azd5462 and the absolute bioavailability of azd5462 in healthy male participants. the study will take place at 1 site in nottingham, and enrol 8 healthy men aged 30-65 years. the study will include 2 periods: * in period 1 volunteers will receive a single dose of radiolabelled test medicine as a liquid by mouth. * in period 2 volunteers will receive a single dose of the test medicine as capsules by mouth and shortly afterwards, a very tiny dose of radiolabelled study medicine by injection into a vein. the participants will be resident in the clinical unit throughout both study periods for a total of 12 nights. the total study duration is approximately up to 6 weeks.

Eligibility criteria:
inclusion criteria: * healthy males aged 30 to 65 years inclusive * bmi in the range 18.0 - 32.0 kg/m2 inclusive and body weight ≥ 50 kg and ≤ 100 kg * regular bowel movements (i.e. average stool production of ≥1 and ≤3 stools per day) exclusion criteria: * history of any clinically significant disease or disorder * history or presence of clinically significant gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs * history of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity * history of active malignancy within 2 years, or under investigation for any form of cancer * participants who do not have suitable veins for multiple venepunctures/cannulation * clinically significant abnormal clinical chemistry, haematology or urinalysis * any clinically significant abnormalities in vital signs * any clinically significant abnormalities on 12-lead ecg * abnormal renal function * radiation exposure exceeding 5 msv in the last 12 months or 10 msv in the last 5 years, occupationally exposed worker, or have been administered imp in a radiolabelled adme study in the last 12 months. * use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins and minerals * current smokers or known or suspected history of alcohol or drug abuse * excessive intake of caffeine-containing drinks or food

Keywords: heart failure
airway management in thoracic anesthesia in italy

Conditions: Mechanical Ventilation Complication

Summary: the aim of this study is to compare the success rate of lung isolation and time to accomplish a correct placement of the device between anesthetists with experience in thoracic anesthesia (defined as at least 4 years clinical practice experience as attending anesthetists in thoracic) and residents in training in thoracic anesthesia.

the aim of this study is to compare the success rate of lung isolation and time to accomplish a correct placement of the device between anesthetists with experience in thoracic anesthesia (defined as at least 4 years clinical practice experience as attending anesthetists in thoracic) and residents in training in thoracic anesthesia. a prospective randomized trial was designed. to check the optimal dlt (broncho-cath covidien, ireland, dublin, teleflex medical, athlone, irelanad) and/or bb (uniblocker, phycon, fuji, japan arndt cohen cook, australia), placement a fiberoptic bronchoscope (fob) was used. the lung collapse was assessed by surgeons. time from laringoscopy to the correct placement of the device, confirmed with fob, was checked. data were analyzed with student't test and chi-square test; p value \< 0.05 was considered to be significant.

Eligibility criteria:
inclusion criteria: * patients who need one lung ventilation undergoing thoracic surgery exclusion criteria: * age \< 18 years old
effectiveness of vibration and standing versus standing alone for the treatment of osteoporosis for people with spinal cord injury.

Conditions: Spinal Cord Injury.; Osteoporosis.

Summary: the purpose of this study is to find out if standing and/or standing with vibration works for the treatment of osteoporosis for people with a spinal cord injury.


Eligibility criteria:
inclusion criteria: * traumatic spinal cord injury of greater than 12 months. * osteopenia or osteoporosis of the hip. exclusion criteria: * pregnant or lactating females. * nonunion lower extremity fracture within the last 6 months. * bilateral hip or knee flexion contractures. * bilateral lower extremity total hip or knee replacement. * heterotopic ossification of the hip or knee. * concurrent treatment with a bisphosphonate.

Keywords: spinal cord injury. osteoporosis. standing. vibration.
safety and efficacy in type 2 diabetic patients with severe chronic renal impairment, 5 mg bi 1356 (linagliptin) vs. placebo, insulin background inclusive

Conditions: Diabetes Mellitus, Type 2

Summary: to determine safety, efficacy and tolerability of bi 1356 versus placebo


Eligibility criteria:
inclusion criteria: * male and female patients with type 2 diabetes and with glomerular filtration rate (gfr) \<30 ml/min, who are not on chronic dialysis. * insufficient glycemic control (hemoglobin a1c (hba1c) between 7.0% and 10.0%) * age 18 or over and not older than 80 years exclusion criteria: * treatment with any other anti diabetic drug other than insulin and/or sulphonylurea within 3 months prior to informed consent * myocardial infarction, stroke or transient ischemic attack (tia) within 6 months prior to informed consent * unstable or acute congestive heart failure
visual health evaluation of new designed blue-blocking glasses

Conditions: Blue-blocking Glasses

Summary: with the widespread use of electronic display devices, the potential hazards of blue light have become an important public health issue. the primary assessment and main outcome indicators of this experiment are the evaluation of the protective effects of a new type of filtering glasses on visual fatigue in the human eye. secondary outcome indicators include tear film break-up time, accommodative facility, and subjective visual fatigue scores. other outcome measurement indicators include visual function indicators such as accommodation and convergence. baseline values of the above indicators were measured separately, and then specific numerical values of different indicators were collected after working with vdt devices while wearing the new type of filtering glasses or regular framed glasses. these values were statistically compared and analyzed with the baseline values. the study aims to assess the impact of the new type of filtering glasses on relieving visual fatigue and improving visual function.


Eligibility criteria:
inclusion criteria: * 1. adult population, regardless of gender 2. refractive error is less than or equal to -2.5d and both eyes achieve corrected visual acuity of 0.8 or higher. 3. normal intraocular pressure with no organic pathology. 4. no apparent symptoms of dry eye. 5. willing to cooperate to complete all the tests. 6. voluntarily signing the informed consent form. exclusion criteria: * 1: individuals with strabismus and amblyopia exist. 2: suffering from congenital eye conditions such as congenital cataracts or congenital retinal diseases. 3: those who have undergone intraocular surgery (such as cataract removal, intraocular lens implantation, etc.). 4: individuals with refractive media opacity (such as corneal lesions, lens opacity, etc.). 5: abnormal intraocular pressure (iop) (iop \ 21 mmhg, or a bilateral iop difference of ≥5 mmhg). 6: abnormal intraocular pressure (iop) (iop \ 21 mmhg, or a bilateral iop difference of ≥5 mmhg). 7: only one eye meets the inclusion criteria. 8: active corneal infections such as bacterial, fungal, viral, or other acute or chronic anterior segment inflammations. 9: currently using medications that may lead to dry eye or affect vision and corneal curvature. 10: other ocular conditions, such as dacryocystitis, eyelid disorders and abnormalities, abnormal intraocular pressure, and glaucoma. 11: unable to undergo regular eye examinations.

Keywords: blue-blocking glasses visual fatigue but cff visual function
thoraco-laparoscopic partial esophagogastrectomy for management of esophageal cancer

Conditions: Esophageal Cancer

Summary: thoraco-laparoscopic partial esophagogastrectomy has emerged as a promising minimally invasive alternative, combining thoracoscopy and laparoscopy to reduce the trauma associated with open surgery.early and intermediate-term outcomes provide critical information on both the oncological efficacy and functional benefits of the procedure. by examining recurrence rates within the first 12-24 months, this study will provide valuable insights into the oncological robustness of this approach compared to more invasive approaches.


Eligibility criteria:
inclusion criteria: * patients diagnosed with resectable esophageal cancer (stages i-iii). * suitable for thoraco-laparoscopic partial esophagogastrectomy. * eastern cooperative oncology group (ecog) performance status 0-2. exclusion criteria: * presence of distant metastasis at diagnosis. * history of previous esophageal or gastric surgery. * contraindications to laparoscopy or thoracoscopy.
examining the efficacy of kiko exercises on the prevention of migraine headaches

Conditions: Migraine Headache

Summary: this pilot study hopes to show that after 3 months of kiko training, kiko naive patients with migraine will have a decrease in the frequency and severity of their migraines.

3.1 study design eligible subjects in this pilot study will be taught a series of kiko exercises. subjects who meet inclusion and exclusion criteria at the screening visit will be given a diary in which they will document their migraine frequency and severity for one month. once subject diaries are complete, subjects will meet for a group lesson to learn the background of kiko and study exercises. a dvd or videotape will be issued for subjects to use during practice at home. subjects will maintain a diary of their migraine headaches, as well as a diary of their exercise routines. subjects will meet weekly to reinforce training and encourage training continuation. diaries will be collected at the end of the first, second, and third months.

Eligibility criteria:
inclusion criteria: * males or females, 18 to 70 years of age, with at least a 1-year history of migraine headaches * with or without aura, (ihs criteria 1.1 and 1.2), who have experienced at least 4 migraines a month, or 2-3 migraines a month that last 2-3 days per attack in each of the 3 months prior to screening. * the subjects must be naïve to kiko and qigong training. exclusion criteria: 1. subject has any cardiac condition, as determined by the investigator, that would preclude safe participation in a low level exercise program. 2. uncontrolled hypertension at screening (sitting systolic pressure \>160 mmhg, diastolic pressure \>95 mmhg.) 3. subject has had tension-type headaches, \>15 days/month in any of the 3 months prior to screening. 4. subject has more than 8 migraines per month, or more than 16 days of migraine per month. 5. subject is pregnant or expects to become pregnant during the course of the trial. 6. subject has substance or alcohol abuse within the the last year which, in the investigator's judgement, will interfere with the study conduct, cooperation or evaluation and interpretation of the study results. 7. subject has any concurrent medical or psychological condition that, in the investigator's opinion, may affect the interpretation of efficacy or safety data or which otherwise contraindicates participation in the trial. 8. subject has participated in an investigational drug trial within the previous 4 weeks. 9. subject uses pain medication in excess of 40 doses of over the counter medication and/or prescription pain medication per month to treat headaches of any type. 10. subject is unable to differentiate between migraine and non-migraine headaches.

Keywords: migraine kiko qigong relaxation exercise
study of families with melanoma

Conditions: Melanoma (Skin)

Summary: rationale: a study that evaluates patients' lifestyle, skin, and blood and tissue samples may help doctors understand the risk factors for melanoma relapse. purpose: this clinical trial is studying the risk factors for melanoma in families with melanoma.

objectives: primary * determine what lifestyle factors and which genes govern relapse from melanoma. secondary * compare sun exposure and genes that cause melanoma in patients with melanoma vs healthy participants. * assess how unusual moles relate to sun exposure and genes that cause melanoma. outline: this is a multicenter, cohort study. patients and healthy participants complete lifestyle questionnaires by mail and telephone. some patients\* and healthy participants undergo a skin examination to count moles and classify skin type (e.g., degree of freckling and wrinkling indicative of sun damage). note: \*patients diagnosed with primary invasive melanoma after september 2005 do not need to consent to a skin examination. patients and healthy participants also undergo blood collection for lymphocyte analysis, dna extraction, and the measurement of minerals, vitamins, and beta carotene. tissue samples from original diagnosis are examined by immunohistochemistry for gene expression and mutations, including cdkn2a and cdk4. patients and healthy participants are followed annually. peer reviewed and funded or endorsed by cancer research uk projected accrual: a total of 3,700 patients and healthy participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * meets 1 of the following criteria: * newly diagnosed primary invasive melanoma (patient group) * lentigo maligna malignant melanoma allowed * rare variants of melanoma allowed, including any of the following: * acral lentiginous * subungual * ear, nose, and throat * oropharyngeal * perineal * vaginal * vulval * rectal * nodal with no known primary * patients undergoing sentinel node biopsy are eligible * no in situ melanoma, melanocytic intraepidermal neoplasia, or ocular melanoma * healthy participant meeting either of the following criteria (control group): * relative of a patient who was diagnosed with melanoma after september 2005 * healthy volunteer who is age- and sex-matched for patients who were diagnosed with melanoma before october 2005 patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: lentigo maligna malignant melanoma stage iv melanoma acral lentiginous malignant melanoma nodular malignant melanoma stage ia melanoma stage ib melanoma stage iia melanoma stage iib melanoma stage iic melanoma stage iiia melanoma stage iiib melanoma stage iiic melanoma